BioNTech and Bristol Myers Squibb report encouraging phase 2 data for pumitamig in lung cancer

what happened

BioNTech and Bristol Myers Squibb reported first data from the global phase 2 ROSETTA Lung-107 trial, according to a joint press release distributed via GlobeNewswire. The companies are testing pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, combined with docetaxel in patients with metastatic non-small cell lung cancer whose disease progressed after first-line immunotherapy plus chemotherapy. The results were presented at the ESMO Congress 2026 in Madrid.

Among 30 efficacy-evaluable patients, the confirmed objective response rate was 36.7%, and the disease control rate reached 90.0%. In the overall group of 50 patients, median progression-free survival was 6.9 months, and the six-month progression-free survival rate was 63.3%. By comparison, standard docetaxel has historically delivered median progression-free survival of about 3.6 to 3.9 months. The companies reported no new safety signals.

why it matters

Shares of BioNTech and Bristol Myers Squibb may react to such data, since the two companies jointly develop pumitamig as a key oncology program. Investors will also watch the plan for further studies, including four ongoing global phase 3 trials. The data come from a small sample with short follow-up, so their market significance will depend on the next stages of development.

market impact

BNTX, BMY: encouraging data for a key oncology drug can shift investor interest in both companies

tags

instruments